Jeffrey Hung
Stock Analyst at Morgan Stanley
(4.02)
# 571
Out of 5,124 analysts
234
Total ratings
53.85%
Success rate
10.64%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jeffrey Hung
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CYTK Cytokinetics | Maintains: Overweight | $65 → $71 | $63.54 | +11.74% | 14 | Dec 23, 2025 | |
| BIOA BioAge Labs | Upgrades: Equal-Weight | $5 → $12 | $13.23 | -9.30% | 3 | Dec 8, 2025 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Overweight | $185 → $205 | $170.00 | +20.59% | 12 | Nov 17, 2025 | |
| ENGN enGene Holdings | Maintains: Overweight | $18 → $19 | $9.03 | +110.41% | 5 | Nov 12, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Overweight | $178 → $173 | $141.83 | +21.98% | 31 | Nov 11, 2025 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Overweight | $122 → $129 | $107.04 | +20.52% | 14 | Oct 16, 2025 | |
| CRNX Crinetics Pharmaceuticals | Maintains: Overweight | $65 → $77 | $46.55 | +65.41% | 3 | Sep 29, 2025 | |
| CGON CG Oncology | Maintains: Overweight | $56 → $79 | $41.52 | +90.27% | 5 | Sep 17, 2025 | |
| PTCT PTC Therapeutics | Maintains: Overweight | $76 → $71 | $75.96 | -6.53% | 13 | Aug 20, 2025 | |
| CGEM Cullinan Therapeutics | Maintains: Overweight | $35 → $28 | $10.35 | +170.53% | 7 | Aug 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $21 | $11.43 | +83.73% | 4 | Aug 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $4 → $2 | $3.72 | -46.24% | 4 | Aug 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $17 → $13 | $7.05 | +84.40% | 6 | Aug 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $102 → $108 | $14.24 | +658.43% | 5 | Jul 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $65 → $55 | $23.00 | +139.13% | 9 | Jul 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $20 → $24 | $26.71 | -10.15% | 25 | May 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $85 | $79.41 | +7.04% | 6 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $27 | $25.01 | +7.96% | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $35 | $7.88 | +344.16% | 1 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $10 → $4 | $2.90 | +37.93% | 10 | Dec 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $1 → $4 | $2.47 | +61.94% | 1 | Dec 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $14 | $6.58 | +112.77% | 3 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $5 | $3.53 | +41.64% | 1 | Jul 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $9 → $3 | $3.70 | -18.92% | 8 | Mar 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $15 → $14 | $2.60 | +438.46% | 7 | Feb 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $50 → $10 | $1.11 | +800.90% | 3 | Jan 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $23 → $22 | $43.83 | -49.81% | 10 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $146 → $149 | $11.29 | +1,215.32% | 2 | May 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $100 → $60 | $0.85 | +6,934.00% | 5 | Aug 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $6 | $3.93 | +52.67% | 9 | Apr 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $696 → $648 | $14.19 | +4,466.60% | 6 | May 8, 2020 |
Cytokinetics
Dec 23, 2025
Maintains: Overweight
Price Target: $65 → $71
Current: $63.54
Upside: +11.74%
BioAge Labs
Dec 8, 2025
Upgrades: Equal-Weight
Price Target: $5 → $12
Current: $13.23
Upside: -9.30%
Jazz Pharmaceuticals
Nov 17, 2025
Maintains: Overweight
Price Target: $185 → $205
Current: $170.00
Upside: +20.59%
enGene Holdings
Nov 12, 2025
Maintains: Overweight
Price Target: $18 → $19
Current: $9.03
Upside: +110.41%
Neurocrine Biosciences
Nov 11, 2025
Maintains: Overweight
Price Target: $178 → $173
Current: $141.83
Upside: +21.98%
Rhythm Pharmaceuticals
Oct 16, 2025
Maintains: Overweight
Price Target: $122 → $129
Current: $107.04
Upside: +20.52%
Crinetics Pharmaceuticals
Sep 29, 2025
Maintains: Overweight
Price Target: $65 → $77
Current: $46.55
Upside: +65.41%
CG Oncology
Sep 17, 2025
Maintains: Overweight
Price Target: $56 → $79
Current: $41.52
Upside: +90.27%
PTC Therapeutics
Aug 20, 2025
Maintains: Overweight
Price Target: $76 → $71
Current: $75.96
Upside: -6.53%
Cullinan Therapeutics
Aug 18, 2025
Maintains: Overweight
Price Target: $35 → $28
Current: $10.35
Upside: +170.53%
Aug 18, 2025
Maintains: Overweight
Price Target: $20 → $21
Current: $11.43
Upside: +83.73%
Aug 18, 2025
Downgrades: Equal-Weight
Price Target: $4 → $2
Current: $3.72
Upside: -46.24%
Aug 12, 2025
Maintains: Equal-Weight
Price Target: $17 → $13
Current: $7.05
Upside: +84.40%
Jul 17, 2025
Upgrades: Overweight
Price Target: $102 → $108
Current: $14.24
Upside: +658.43%
Jul 14, 2025
Maintains: Overweight
Price Target: $65 → $55
Current: $23.00
Upside: +139.13%
May 20, 2025
Maintains: Equal-Weight
Price Target: $20 → $24
Current: $26.71
Upside: -10.15%
Mar 7, 2025
Assumes: Overweight
Price Target: $85
Current: $79.41
Upside: +7.04%
Mar 7, 2025
Assumes: Overweight
Price Target: $27
Current: $25.01
Upside: +7.96%
Jul 26, 2024
Initiates: Overweight
Price Target: $35
Current: $7.88
Upside: +344.16%
Dec 19, 2023
Downgrades: Underweight
Price Target: $10 → $4
Current: $2.90
Upside: +37.93%
Dec 19, 2023
Upgrades: Equal-Weight
Price Target: $1 → $4
Current: $2.47
Upside: +61.94%
Aug 4, 2023
Maintains: Equal-Weight
Price Target: $14
Current: $6.58
Upside: +112.77%
Jul 11, 2023
Reiterates: Equal-Weight
Price Target: $5
Current: $3.53
Upside: +41.64%
Mar 20, 2023
Maintains: Equal-Weight
Price Target: $9 → $3
Current: $3.70
Upside: -18.92%
Feb 27, 2023
Maintains: Equal-Weight
Price Target: $15 → $14
Current: $2.60
Upside: +438.46%
Jan 30, 2023
Downgrades: Underweight
Price Target: $50 → $10
Current: $1.11
Upside: +800.90%
Nov 2, 2022
Maintains: Equal-Weight
Price Target: $23 → $22
Current: $43.83
Upside: -49.81%
May 11, 2022
Maintains: Equal-Weight
Price Target: $146 → $149
Current: $11.29
Upside: +1,215.32%
Aug 13, 2021
Downgrades: Underweight
Price Target: $100 → $60
Current: $0.85
Upside: +6,934.00%
Apr 19, 2021
Maintains: Equal-Weight
Price Target: $7 → $6
Current: $3.93
Upside: +52.67%
May 8, 2020
Maintains: Overweight
Price Target: $696 → $648
Current: $14.19
Upside: +4,466.60%